Dolby Laboratories (NYSE:DLB) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Dolby Laboratories (NYSE:DLB – Get Free Report) released its earnings results on Tuesday. The electronics maker reported $1.25 EPS for the quarter, topping the consensus estimate of $1.20 by $0.05, FiscalAI reports. The company had revenue of $373.54 million during the quarter, compared to analysts’ expectations of $372.76 million. Dolby Laboratories had a net margin of 16.70% and a return on equity of 11.08%. Dolby Laboratories updated its Q1 2027 guidance to 0.410-0.560 EPS and its FY 2027 guidance to 4.270-4.420 EPS.

Dolby Laboratories Stock Performance

NYSE:DLB traded down $2.56 during trading hours on Tuesday, hitting $58.60. The company’s stock had a trading volume of 4,085,503 shares, compared to its average volume of 842,639. Dolby Laboratories has a 52-week low of $48.26 and a 52-week high of $69.95. The business’s 50-day moving average is $60.97 and its two-hundred day moving average is $59.43. The company has a market capitalization of $5.49 billion, a PE ratio of 24.94 and a beta of 0.79.

Latest Dolby Laboratories News

Investors following DLB have been watching these news items:

  • Positive Sentiment: Zacks Research made small upward revisions to several 2027–2028 EPS estimates, including its FY2028 forecast to $3.40 from $3.38, though it maintained a Hold rating.
  • Neutral Sentiment: Trading volume was substantially above its average, suggesting heightened investor activity around the earnings release; the reports do not establish what drove the market’s reaction.
  • Negative Sentiment: Rosenblatt Securities cut its price target to $80 from $85. It retained a Buy rating, so the revision was a less-bullish valuation view rather than a downgrade.

Analyst Upgrades and Downgrades

DLB has been the topic of a number of recent analyst reports. Zacks Research upgraded shares of Dolby Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday. Rosenblatt Securities reduced their price objective on shares of Dolby Laboratories from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Monday. Weiss Ratings raised Dolby Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, September 9th. Finally, Wall Street Zen lowered Dolby Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.00.

Get Our Latest Report on Dolby Laboratories

Insider Buying and Selling at Dolby Laboratories

In other news, SVP John Couling sold 7,667 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $58.78, for a total transaction of $450,666.26. Following the transaction, the senior vice president directly owned 166,803 shares of the company’s stock, valued at $9,804,680.34. This represents a 4.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Ryan Nicholson sold 1,183 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $65.28, for a total transaction of $77,226.24. Following the completion of the transaction, the chief accounting officer owned 34,453 shares of the company’s stock, valued at $2,249,091.84. This represents a 3.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,517 shares of company stock worth $995,963 over the last 90 days. Insiders own 37.93% of the company’s stock.

Dolby Laboratories declared that its board has initiated a stock buyback program on Thursday, July 30th that allows the company to repurchase $350 million in outstanding shares. This repurchase authorization allows the electronics maker to repurchase up to 7% of its shares through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Dolby Laboratories Company Profile

(Get Free Report)

Dolby Laboratories, Inc. develops audio and imaging technologies used in entertainment and consumer electronics. Its offerings include Dolby Atmos immersive audio, Dolby Vision high-dynamic-range imaging, and technologies for encoding, delivering and reproducing sound and video. The company licenses its technologies to manufacturers and content businesses across areas such as film, television, streaming, gaming and mobile devices. Dolby also supports cinema experiences through technologies and services including Dolby Cinema.

Read More

Earnings History for Dolby Laboratories (NYSE:DLB)

Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.